VENUS MEDTECH-B(02500.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 191.31 million, loss widened by 41.95% YoY

NewTimeSpace (newtimespace.com) News, August 31, 2026, VENUS MEDTECH-B(02500.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 135.5 million, decreased by 27.59% YoY; Net Profit stood at loss of CNY 191.31 million, loss widened by 41.95% YoY; Profit Attributable to Shareholders stood at loss of CNY 191.31 million, loss widened by 41.95% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.44.

In terms of profitability, VENUS MEDTECH-B Gross Profit changed from CNY 137.99 million in the same period last year to CNY 93.52 million in the current period, decreased by CNY 44.47 million; gross profit margin changed from 73.74% in the same period last year to 69.02% in the current period, decreased by 4.72 percentage points; net profit changed from loss of CNY 134.77 million in the same period last year to loss of CNY 191.31 million in the current period, decreased by CNY 56.54 million; net profit margin changed from -72.02% in the same period last year to -141.19% in the current period, decreased by 69.17 percentage points.
In terms of earnings quality, VENUS MEDTECH-B Operating Profit changed from loss of CNY 129.13 million in the same period last year to loss of CNY 183.01 million in the current period, decreased by CNY 53.88 million; Operating Profit Margin changed from -69% in the same period last year to -135.06% in the current period, decreased by 66.06 percentage points.
In terms of financial soundness, VENUS MEDTECH-B Debt-to-Asset Ratio changed from 33.77% in the same period last year to 31.37% in the current period, decreased by 2.4 percentage points; Total Equity changed from CNY 2.066 billion in the same period last year to CNY 1.526 billion in the current period, decreased by CNY 540.22 million; Current Liabilities changed from CNY 403.32 million in the same period last year to CNY 354.63 million in the current period, decreased by CNY 48.69 million; Quick Ratio changed from 1.56 in the same period last year to 1.04 in the current period, decreased by 0.52 percentage points.
In terms of R&D investment focus, VENUS MEDTECH-B R&D Expenses changed from CNY 120.93 million in the same period last year to CNY 128.66 million in the current period, increased by CNY 7.73 million; R&D to Total Revenue Ratio changed from 64.62% in the same period last year to 94.95% in the current period, increased by 30.33 percentage points.
By the close of trading on August 31, 2026, VENUS MEDTECH-B(02500) saw a gain of 0.5% in its share price, closing at HKD 1.005. The full-day turnover stood at HKD 382.35 thousand, with the latest market capitalization at HKD 443.22 million.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.